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Abstract Barrett’s esophagus (BE) is an acquired condi-
tion in which the normal lining of the esophagus is replaced
by intestinal metaplastic epithelium. BE can evolve to
esophageal adenocarcinoma (EAC) through low-grade
dysplasia (LGD) and high-grade dysplasia (HGD). The
only generally accepted marker for increased risk of EAC is
the presence of HGD, diagnosed on endoscopic biopsies.
More specific markers for the prediction of EAC risk are
needed. A tissue microarray was constructed comprising
tissue samples from BE, LGD, HGD, and EAC. Marker
expression was studied by immunohistochemistry using
antibodies against CD44, DKK1, CDX2, COX2, SOX9,
OCT1, E-cadherin, and β-catenin. Immunostaining was
evaluated semi-quantitatively. CD44 expression decreased
in HGD and EAC relative to BE and LGD. DKK1
expression increased in HGD and EAC relative to BE
and LDG. CDX2 expression increased in HGD but
decreased in EAC. COX2 expression decreased in EAC,
and SOX9 expression increased only in the upper crypt
epithelial cells in HGD. E-cadherin expression decreased in
EAC. Nuclear β-catenin was not significantly different
between BE, LGD, and HGD. Loss of CD44 and gain of
DKK1 expression characterizes progression from BE and
LGD to HGD and EAC, and their altered expression might
indicate an increased risk for developing an EAC. This
observation warrants inclusion of these immunohistochemi-
cally detectable markers in a study with a long patient
follow-up.
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Introduction
Barrett’s esophagus (BE) is an acquired condition defined
as the replacement of normal stratified squamous epithelium
by metaplastic columnar epithelium in the distal esophagus
[1–3]. BE is acquired due to prolonged gastro-esophageal
reflux disease (GERD) which is increasing in incidence [4].
BE is a preneoplastic condition as it predisposes to the
development of esophageal adenocarcinoma (EAC) via
progression along low-grade dysplasia (LGD) and high-
grade dysplasia (HGD). EAC is rapidly increasing in the
western world; the incidence has increased over 70% in the
last 20 years [5]. Almost without exception, EAC develops
in BE [6] and, therefore, early recognition of this condition
and endoscopic follow-up are potentially effective ways to
prevent EAC.
BE evolves into EAC stepwise through increasing
grades of dysplasia. As yet, the marker used for clinical
decision making on eventual therapeutic intervention in a
BE patient is the presence of HGD in endoscopic biopsies
(during the follow-up of BE patients or a newly diagnosed
GERD patient). In the presence of HGD, the patient runs a
risk of over 40% to develop an EAC, and HGD is therefore
an indication for an intervention, which used to be
esophagectomy, but lately, more conservative approaches
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such as photodynamic therapy or mucosectomy have been
developed [7, 8]. An important problem, however, is that of
all patients with BE, only about 0.5% per year will
eventually develop an adenocarcinoma [9]. A large number
of patients are therefore kept under surveillance for the
detection of a relatively small number of cancers. Conse-
quently, markers are needed for the prediction of cancer risk
in BE patients before HGD has developed.
Various attempts have been made to identify markers
that can predict whether or not a BE patient will develop an
EAC. Approaches chosen have included morphometry, cell
adhesion molecule expression, DNA ploidy analysis, loss
of heterozygosity at the chromosomal level, p53 mutations
and immunohistochemical overexpression, proliferative
activity (through immunohistochemical staining of the
Ki-67 antigen), p16 anomalies (including promoter meth-
ylation, mutations, and loss of heterozygosity), activation of
the Wnt pathway (through adenomatous polyposis coli
mutations, β-catenin mutations, or one of the other players
in Wnt signaling), analysis of patterns of promoter
methylation, and more [10–16]. Although a voluminous
literature exists on this subject, as yet, the only clinically
used biomarker with a high predictive value is the presence
of HGD [10].
In this study, we addressed this problem by examining
the expression of genes involved in the Wnt pathway, Wnt
downstream genes and key homeobox signaling pathway
genes in the normal esophagus, BE with and without
dysplasia, and EAC. The genes included in the study were
selected based on their involvement in directing differenti-
ation, including tissue architecture, in the gastrointestinal
tract. The importance of these genes in gastrointestinal
cancer has been repeatedly stipulated but almost never in
BE or in EAC [13, 17–23]. Their expression was studied in
retrospectively collected tissue samples selected from
surgical resection specimens. The potentially predictive
markers must subsequently be validated in a study on
Barrett patients with long-term follow-up.
Materials and methods
Selection of cases
The cases selected concerned a consecutive series of
esophagectomy specimens received by the University
Institute of Pathology in Lausanne, diagnosed as EAC
between 1995 and 2007 (52 cases). Cases with insufficient
tissue available (either having been used in previous studies
or used in the diagnostic work-up) were excluded. In all, 44
cases were available for study. After re-assessment of the
diagnosis by two experienced pathologists (WS and FB), 31
cases were retained based upon the following criteria:
presence of at least one or more areas of adenocarcinoma
and/or HGD and/or LGD and/or intestinal metaplasia. The
use of human tissues in this study was according to the
criteria for the use of archival specimens as established by
the local ethics review board.
Tissue microarray creation
Tissue samples to be included in the tissue microarray
(TMA), notably with EAC, HGD, LGD, and BE, were
identified on H&E stained tissue sections. From the 31 cases,
122 different tissue samples were included. Control tissue
samples included in each TMA block comprised samples
randomly selected from surgical resection specimens (normal
ileum, normal duodenum, normal colon, normal esophagus,
adenocarcinoma of the colon, and diffuse type and intestinal
type adenocarcinoma of the stomach).
The TMAs were created in paraffin-embedded blocks of
2% agarose (Sigma A5093) mounted on a cassette using a
manual TMA maker (Beecher Instruments Inc., Sun Prairie,
WI, USA), as described previously [24]. Each TMA
consisted of a 6×7 grid of 2 mm cores, allowing up to 41
tissue cores per TMA (one varying position was left empty
for TMA recognition and proper orientation). Overall, four
TMA blocks were constructed including 158 cores (64
EAC, 17 HGD, 19 LGD, and 22 BE samples and 36 control
tissue samples). Sections (4 μ) were cut, stretched on a 56°C
water bath, and mounted on SuperFrost Plus microscope
slides (Menzel GmbH & Co KG, Braunschweig, Germany).
On one H&E stained section, a final reference diagnosis was
made for each tissue core (WS and FTB); this diagnosis was
used in the study.
Selection of antibodies
Our selection of the target proteins was based upon the
hypothesis that Wnt signaling and Wnt downstream genes
play a key role in EAC development, in analogy to gastric
and colorectal cancer. A first selection was made on the
involvement of Wnt target genes in human gastrointestinal
carcinogenesis as mentioned on the Wnt homepage (http://
www.stanford.edu/~rnusse/wntwindow.html). A final selec-
tion was made based upon the published literature supporting
potential involvement of the various proteins in gastrointes-
tinal mucosa differentiation or in intestinal carcinogenesis
[13, 18, 19, 25–31] and on the available antibodies applicable
to routinely processed tissue specimens. As a readout protein
for Wnt pathway activation, nuclear localization of β-catenin
was used. As Wnt downstream proteins, we chose CD44,
COX2, E-cadherin, CDX2, DKK1, and SOX9. Two homeo-
box proteins (CDX2 and OCT1) were included in the study,
based on earlier reports indicating involvement of these
proteins in intestinal metaplasia/dysplasia [21, 25, 30, 31].
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Immunohistochemistry
Immunohistochemistry (IHC) was performed either manu-
ally or using an automated system (as indicated in Table 1).
The choice of using one system or the other was based
upon the quality of the staining obtained, some antibodies
requiring a specially adapted protocol not easily adaptable
to the staining machine.
Manual immunoperoxidase staining was performed, after
dewaxing, quenching of endogenous peroxidase activity (by
incubation with 3% hydrogen peroxide in demineralized water
for 5 min), and antigen retrieval (2 min in a pressure cooker in
ethylenediaminetetraacetic acid (EDTA) buffer, pH 9.0), using
Envision+ (DAKO, Glostrup, Denmark) as detection system
[24]. Exposure to primary antibodies, diluted as indicated in
Table 1, was 2 h at room temperature. Visualization was
performed with diaminobenzidine tetrachloride as chromogen.
Sections were counterstained with hematoxylin.
Automated IHC was performed using the Bond IHC
stainer (Vision BioSystems, Mount Waverley, Australia)
with as secondary reagent, anti-goat Histofine max polymer
(Nichirei Biosciences, Tokyo, Japan). Key program sequences
were antigen retrieval (with EDTA buffer pH 9.0 for 20 min at
95°C or citrate buffer pH 9.0 for 20 min at 100°C), primary
antibody incubation for 30 min, and incubation with the
polymer kit for 15 min. In all experiments, negative control
incubations (omission of the primary antibody) and positive
control tissues were included.
Assessment of immunoreactivity
The immunoreactivity was microscopically evaluated inde-
pendently by two observers (WS and PY) in terms of the
percentage of cells stained (in deciles). Given the zonal
architecture of BE mucosa, the percentage of positive cells
was noted separately for the upper crypt half and the lower
crypt half in BE, LGD, and HGD but only as a percentage
of all cells in EAC. No major discrepancies occurred
between the two assessors; the mean of the two assessments
was used for statistical calculations.
Data was entered in SPSS version 15.0 for Windows
(SPSS Inc., Chicago, IL, USA), and descriptive analysis
was undertaken, together with a one-way ANOVA test to
assess statistical significance between the values obtained
for localization and diagnostic category. For comparison
between BE, LGD, and HGD, upper and lower crypt half
were considered separately. For comparisons with EAC, the
highest (either upper of lower) crypt value was used.
Differences between diagnostic categories were analyzed
using Tukey’s honestly significant difference post hoc test,
graphically visualized by box-plot graphs. In the graphs, for
the sake of clarity, outliers have been indicated separately
(with the symbols white circle or filled star in the figures, the
numbers referring to the outlying sample number), but the
data points were included in the statistical calculations.
The number of samples available precluded the use of
validated statistical approaches (receiver operating charac-
teristic (ROC) analysis) to determine eventual cut-points. To
explore potential diagnostic use of thesemarkers, we arbitrarily
chose 30% loss of CD44 (absence of membranous immunos-
taining in at least 30% of the cells) and 30% gain of DKK1
(cytoplasmic staining of at least 30% of cells) as cut-points.
Results
The results obtained by scoring of the immunostained TMAs
are illustrated in the figures and summarized in Table 2. We will
briefly describe immunoreactivity patterns per studied antigen.
CD44 and DKK1
In general, CD44 immunoreactivity was found on the
plasma membrane of epithelial cells. A minority of the
Table 1 Antibodies used with their dilution, antigen retrieval method, and immunohistochemistry method
Antigen Source Clone Species Concentration IHC method
ß-catenin Novocastra 17C2 Mouse 1:100 A
CD44 CHUV Wild-type PCA Mouse 1:50 A
COX2 Cayman synth pept Mouse 1:1,000 B
DKK1 Lifespan PCA Rabbit 1:100 B
E-cadherin DAKO NCH-3.8 Mouse 1:40 A
CDX2 Novocastra AMT28 Mouse 1:50 A
OCT1 LabVision PCA Rabbit 1:50 A
SOX9 Chemicon PCA Rabbit 1:400 A
A: manual Envision system (DAKO, Glostrup, Denmark), heat-induced epitope retrieval: pressure cooker 2 min EDTA pH 9.0
B: bond automated IHC system (Vision BioSystems, Mount Waverley, Australia), heat-induced epitope retrieval in EDTA pH 9.0
PCA polyclonal antibody
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epithelial cells expressed CD44 circumferentially; the vast
majority showed focal membrane expression. Stromal cells
also stained strongly but were not included in the cell count.
Significant loss of CD44 staining of crypt epithelial cells was
found in HGD in comparison with BE and LGD (Fig. 1a–c).
This was also found for CD44 staining in HGD and EAC vs
BE and LGD, as graphically illustrated in Fig. 1d.
DKK1 stained the cytoplasm with appreciable differ-
ences in intensity between samples. EAC showed more
intense immunoreactivity (Fig. 2a–c). More lower crypt
cells expressed DKK1 in HGD than in BE and LGD. In
EAC, strong diffuse cytoplasmic immunoreactivity was
noted. Overall, DKK1 expression was significantly higher
in HGD and EAC than in BE and LGD (Fig. 2d; Table 2).
Given the consistent differences in CD44 and DKK1
expression notably between LGD and HGD, we chose as
arbitrary cut-points 30% loss of CD44 and 30% gain of
DKK1 expression. With these parameters, the combination
of loss of CD44 and gain of DKK1 was only found in HGD
samples but with low (29%) sensitivity for HGD (Table 3).
Altered expression of at least one marker attained high
specificity and sensitivity (94% and 80%, respectively).
CDX2
CDX2 was only expressed in the nuclei of epithelial cells.
EAC often stained diffusely. CDX2 expression was
significantly higher in upper crypt epithelium in HGD than
in upper crypt epithelium in BE (Fig. 3a–c; Table 2).
Overall, CDX2 expression was significantly lower in EAC
than in HGD (Fig. 3d; Table 2).
SOX9
SOX9 showed a nuclear staining pattern with limited
variation between tissue samples. In some HGD cases,
strong SOX9 staining was noted in upper crypt epithelium
(Fig. 4a, b). SOX9 expression was not strikingly increased
in each HGD case but, overall, significantly higher in HGD
than in BE or LGD (Fig. 4c).
Table 2 Semiquantitative results of immunohistochemical staining
Antibody BE LGD HGD EAC p value Significant between diagnoses
Mean SD Mean SD Mean SD Mean SD
CD44 Crypt 86 18 85 13 53 30 <0.001 BE and LGD vs HGD
Upper 44 33 46 36 40 36 0.843
Total 86 18 85 13 47 36 48 37 <0.001 BE and LGD vs HGD and EAC
DKK1 Crypt 19 12 21 20 49 28 0.001 BE and LGD vs HGD
Upper 11 13 19 26 29 33 0.084
Total 16 15 21 25 35 37 51 35 <0.001 BE and LGD vs EAC
CDX2 Crypt 50 27 59 23 61 26 0.264
Upper 32 25 43 33 63 23 0.005 BE vs HGD
Total 48 28 48 33 66 23 33 34 0.002 HGD vs EAC
OCT1 Crypt 33 26 42 28 47 27 0.320
Upper 20 23 26 28 32 30 0.349
Total 28 29 35 31 41 32 29 30 0.446
SOX9 Crypt 95 4 94 2 95 5 0.720
Upper 81 11 79 21 93 5 0.010 BE and LGD vs HGD
Total 95 4 89 22 96 4 89 15 0.100
COX2 Crypt 93 15 93 21 94 12 0.982
Upper 91 14 90 23 96 10 0.582
Total 95 8 93 21 96 10 73 24 <0.001 BE, LGD, and HGD vs EAC
E-cadherin Crypt 100 1 100 0 100 0 0.480
Upper 100 1 100 0 100 0 0.490
Total 100 1 100 0 100 0 79 31 <0.001 BE, LGD, and HGD vs EAC
β-catenin Cytoplasm 97 11 96 18 72 33 63 34 <0.001 BE and LGD vs EAC
Nuclear 0 0 1 3 1 3 6 14 0.150
Results of descriptive and statistical analysis for obtaining p values using ANOVA test. ATukey’s honestly significant difference post hoc test was
performed for assessing the significance of the differences between diagnoses. As statistically significant, we considered p<0.05. Mean and SD
values are noted in percentages
632 Virchows Arch (2009) 454:629–637
COX2
COX2 showed strong immunoreactivity in the cytoplasm
of epithelial cells (Fig. 5a, b). In EAC, expression was
lower (Fig. 5c). In BE, LGD, and HGD, COX2 expression
was significantly higher than in EAC (Fig. 5d). COX2 was
also expressed in inflammatory cells, notably macro-
phages, but this was not taken into account in scoring
the results.
OCT1
OCT1 was expressed in nuclei of epithelial and stromal
cells. In BE, crypt cell nuclei were most intensely stained.
Significant differences were not noted between LGD and
HGD or EAC (data not shown).
E-cadherin
E-cadherin was strongly immunostained with a membra-
nous pattern in all samples with the exception of EAC. In
EAC, staining was decreased and very heterogeneous (data
not shown), some areas retaining E-cadherin expression and
others with complete loss. In the invasion front in EAC,
individual invasive cells did not show membranous staining
but occasionally cytoplasmic staining.
Fig. 2 DKK1 expression in BE (a), HGD (b), and EAC (c). Cytoplasmic
DKK1 expression was focal and weak in BE, more widespread in HGD,
and strong in EAC. d Box plot of percentage of cells expressing DKK1
per diagnostic category (BE and LGD vs EAC, p<0.001)
Fig. 1 CD44 staining in BE (a), HGD (b), and EAC (c). Crypt cells in
BE show strong membranous staining, which is lost in HGD and
EAC. Note that stromal cells also show CD44 immunoreactivity. d
Box plot of the percentage of CD44 positive cells per diagnostic
category (BE and LGD vs HGD and EAC, p<0.001)
Table 3 Sensitivity and specificity of CD44 loss and DKK1 gain for
the differentiation between LGD and HGD
Marker expression Histology
HGD LGD Total
CD44L/DKK1G 5 0 5
CD44L/DKK1N or CD44N/DKK1G 11 4 15
CD44N/DKK1N 1 15 16
Total 17 19 36
CD44L=CD44 loss (more than 30% of cells)
CD44N=normal pattern of CD44 expression
DKK1G=gain in DKK1 expression (more than 30% of the cells)
DKK1N=less than 30% DKK1 expression
Specificity of CD44L/DKK1G for HGD 5/5=100%
Sensitivity of CD44L/DKK1G for HGD 5/17=29%
Specificity of at least one aberrant marker for HGD 16/17=94%
Sensitivity of at least one aberrant marker for HGD 16/20=80%
Specificity of CD44N/DKK1N for LGD 15/19=79%
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β-catenin
In BE and LGD, strong membranous staining was found.
BE and LGD showed a higher percentage of β-catenin
positive cells than EAC. Nuclear staining was found almost
exclusively in EAC (Fig. 6). Statistical analysis indicated a
significant decrease in membranous β-catenin expression in
EAC (Table 2).
Discussion
The aim of this study was to identify proteins that show
altered expression during the progression of BE to EAC,
with as final goal the definition of markers that will allow
the identification of BE patients with a high risk for EAC
development. Gene expression profiling studies with this
aim have been published [32] but, as yet, have not resulted
in significant progress.
In the design of the study, several elements merit brief
consideration. Firstly, the choice of the material studied: we
conducted the study on a limited number of tissue samples
(122) from 31 patients. We do not consider the small
number of patients an important limitation in our study, as
the intention was to identify promising markers rather than
validating them in a long-term follow-up case control
approach. Therefore, the endpoint we used was not patient
outcome but histological diagnosis per sample. Further
studies would have to include BE and LGD samples from
patients who did not develop HGD or EAC.
A second consideration is our choice to score immuno-
reactivity in BE, LGD, and HGD separately in the lower
and the upper crypt. This division is somewhat arbitrary
and could be subject to inter-observer variation. We
attempted to improve the reproducibility of the scoring
results through implication of two independent observers.
These obtained very similar results, confirming the reliability
of our observations. A further consideration is the way we
compared BE, LGD, and HGD with EAC. As in EAC,
mucosal architecture is completely lost, rendering lower and
upper crypt scores without meaning; we compared scores in
EAC with the highest score (either upper crypt or lower
crypt) in LGD and HGD for our statistical evaluations. We
Fig. 4 Nuclear SOX9 expression was observed in BE mainly in the
lower crypt region (a) but in HGD, extended all the way to the surface
(b). c Box plot of the percentage SOX9 positive cells per diagnostic
category (BE and LGD vs HGD and EAC, p=0.01)
Fig. 3 CDX2 expression in BE (a), HGD (b), and EAC (c).Nuclear
expression was observed in BE in the crypt epithelium, extending to
upper crypt epithelium all the way to the surface in HGD. CDX2
expression was decreased in EAC. d Box plots of the percentage of
CDX2 positive cells per diagnostic category (BE vs HGD, p=0.005;
HGD vs EAC, p=0.002)
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deem this justified as no important differences were noted
when the mean of the two values was used.
Finally, we scored immunoreactivity as a continuous
variable rather than in terms of positive or negative, as cut-
points could not be established using validated statistical
approaches (e.g., ROC analysis). Using this experimental
design, we found the expression of several of the studied
markers to differ significantly between BE, LGD, HGD,
and EAC. Taking as an arbitrary cut-point 30% loss of
CD44 and 30% gain of DKK1 expression, the combination
of these two markers seems promising.
CD44 and DKK1
CD44 has been extensively studied in colorectal cancer [33]
and, also, in BE where decreased expression of wild-type
CD44 in glandular epithelium was reported [34, 35] with a
shift from focal in BE to more diffuse in BE with dysplasia.
We found wild-type CD44 expression to have significantly
decreased in the crypt base epithelium only in HGD, which
is in contrast to the findings of Menges et al. [35, 36]. Also,
in EAC, we noted a decreased level.
Dickkopf-1 (DKK1) is a Wnt antagonist protein that
specifically inhibits Wnt canonical signaling by interacting
with the co-receptor Lrp-5/6 and, thus, prevents Wnt and
Frizzled from forming a ternary complex with Lrp-5/6 [37].
Expression of members of the DKK1 family has been
studied before in colorectal cancer, showing a differential
expression pattern between normal colon epithelium and
colorectal cancer [29]. However, epigenetic silencing of
DKK1 has been reported in colorectal cancer [38, 39].
DKK1 has been studied before in reflux esophagitis and in
BE but not in EAC [40]. We found DKK1 expression to
have increased significantly in HGD and EAC in compar-
ison with BE and LGD. This result is counterintuitive, as
silencing of its repressor conceptually should to go along
with activated Wnt signaling. Overexpression of a repressor
could, however, also signify activation downstream of its
site of action, sustained expression being the result of a
defective feedback loop. It has in addition been reported
that DDK1 may inhibit tumorigenesis through Wnt path-
way independent mechanisms.
In all, loss of CD44 and gain of DKK1 expression might
be taken as indicators of the progression from LGD to
HGD. This is a novel finding and warrants detailed study,
including confirmation by western blotting and reverse
transcription polymerase chain reaction, as a marker for
progression of BE to EAC.
CDX2, OCT1, SOX9, and COX2
The caudal-related homeobox gene CDX2 encodes an
intestine-specific transcription factor crucial for the regulation
of differentiation of intestinal cells [21]. Immunostaining of
CDX2 has been proposed as a useful marker for the
identification of intestinal metaplasia in BE [15, 25, 31,
41]. Overall, we observed increased CDX2 expression in
Fig. 6 β-catenin expression shows a strong membranous immunos-
taining pattern in BE (a) but a nuclear staining pattern in EAC (b)
Fig. 5 Diffuse cytoplasmic COX2 expression was found in BE (a),
LGD, and HGD. The percentage of COX2 positive cells was
decreased in EAC (b). c Box plot of the percentage of COX2 positive
cells per diagnostic category (BE, LGD and HGD vs EAC, p<0.001)
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HGD relative to BE and LGD, which then decreases in
EAC. The widely varying values in individual cases
preclude the use of CDX2 for the diagnosis of HGD. Our
observations match those of Villanacci et al. [25]. It has been
reported that CDX2 expression is modulated by OCT1, but
we did not find OCT1 expression to differ significantly
between the diagnostic categories, suggesting that the
changes in CDX2 expression we observed are not due to
concomitant changes in OCT1 expression, as previous
research suggests [21]. How CDX2 and OCT1 interact
remains largely unclear, and more research on this subject
has to be conducted.
SOX genes constitute a family of transcription factors,
belonging to a super-family known as the high mobility
group box and play an important role in, among others, the
development of the intestinal tract [42]. SOX9 has been
reported to be regulated by the Wnt pathway, and it
represses CDX2 expression in intestinal crypts [43].
We found SOX9 expression to have slightly but
significantly increased in upper crypt epithelium in HGD.
For SOX9 and CDX2 to both show increased expression in
the upper crypt epithelium in HGD was an unexpected
result, given the repressive influence of SOX9 on CDX2
expression [43]. In the regulation of CDX2 expression,
evidently, other factors than only SOX9 are involved. The
wide variation in expression of SOX9 in individual cases
precludes its use for diagnostic purposes.
COX2 was shown to be functionally active in BE since
treatment with COX2 inhibitors reduced proliferative
activity of BE cells in culture as well as of EAC cells [2].
COX2 polymorphisms have been reported to be associated
with increased risk for EAC [44]. An effect of the
polymorphism studied (the 8473 C allele) on the immuno-
histochemical expression level was, however, not reported. We
found the percentage of COX2 expressing cells were signifi-
cantly reduced in EAC, relative to the other disease categories.
This matches the results obtained by Villanacci et al. [25], who
attributed the lower expression of COX2 to the poor
differentiation grade of the EAC in their series. In our group
of EAC, the number of poorly differentiated EACs was also
high. Our data, notably the absence of any difference in COX2
expression between BE, LGD, and HGD, imply that COX2 is
not a potential marker for progression of BE towards EAC.
E-cadherin and β-catenin
E-Cadherin belongs to the family of the cadherin trans-
membrane proteins, which play an important role in cell
adhesion notably in the formation of adherence junctions
through homotypic interactions. Earlier studies on the
involvement of E-cadherin in the development of EAC
suggest that there is decreased expression with progressive
degrees of dysplasia [26, 45]. Although we were unable to
reproduce the differences between LGD and HGD, we did
find a significant decrease in EAC relative to HGD. E-
cadherin is more likely related to the development of
invasive activity and, as such, a marker of EAC. A role in
the discrimination between BE and LGD on one hand and
HGD on the other is unlikely.
Nuclear β-catenin is an indicator of canonical Wnt
activation. When accumulating in the nucleus, β-catenin
forms a complex with lymphoid enhancer factor (LEF1),
T-cell factor (TCF4), and other transcription factors [13].
Unlike in many other carcinomas, mutations in the β-catenin
gene do not play a role in EAC [46], the mechanisms
involved in Wnt activation having been incompletely
resolved to date. The key regulators of the Wnt pathway in
EAC are probably different from those in other carcinomas
as is stated by Clement et al. [12]. We found no statistically
significant differences in β-catenin expression between BE
and LGD or HGD. The Wnt pathway is likely to be involved
in the development of EAC [12, 13] but in EAC invasion
rather than in the progression from BE to dysplasia.
In conclusion, our data indicate that loss of CD44 and
gain of DKK1 expression characterizes the transition from
LGD to HGD, which might go along with an increased risk
for developing an EAC. This observation warrants their
inclusion into a follow-up study. The first goal of this study
would be to confirm our findings in a larger series of cases.
Ultimately, when these findings are confirmed, these
markers should be included in a prospective clinicopatho-
logical study with long-term patient follow-up to confirm
their significance as indicators for an increased risk for the
development of EAC from BE.
Conflict of interest We declare that we have no conflict of interest.
References
1. Flejou JF (2000) Barrett’s oesophagus: from metaplasia to
dysplasia and cancer. Gut 54(Suppl 1):i6–i12
2. Koppert LB, Wijnhoven BP, van Dekken H et al (2005) The
molecular biology of esophageal adenocarcinoma. J Surg Oncol
92:169–190
3. Playford RJ (2006) New British society of gastroenterology
(BSG) guidelines for the diagnosis and management of Barrett’s
oesophagus. Gut 55:442
4. el-Serag HB, Sonnenberg A (1998) Opposing time trends of
peptic ulcer and reflux disease. Gut 43:327–333
5. Blot WJ, McLaughlin JK (1999) The changing epidemiology of
esophageal cancer. Semin Oncol 26(5 Suppl 15):2–8
6. Farrow DC, Vaughan TL (1996) Determinants of survival
following the diagnosis of esophageal adenocarcinoma (United
States). Cancer Causes Control 7:322–327
7. Falk GW, Rice TW, Goldblum JR et al (1999) Jumbo biopsy
forceps protocol still misses unsuspected cancer in Barrett’s
esophagus with high-grade dysplasia. Gastrointest Endosc
49:170–176
636 Virchows Arch (2009) 454:629–637
8. Heitmiller RF, Redmond M, Hamilton SR (1996) Barrett’s
esophagus with high-grade dysplasia. An indication for prophy-
lactic esophagectomy. Ann Surg 224:66–71
9. Shaheen NJ, Crosby MA, Bozymski EM et al (2000) Is there
publication bias in the reporting of cancer risk in Barrett’s
esophagus? Gastroenterology 119:333–338
10. Flejou JF, Svrcek M (2007) Barrett’s oesophagus—a pathologist’s
view. Histopathology 50:3–14
11. Morales CP, Souza RF, Spechler SJ (2002) Hallmarks of cancer
progression in Barrett’s oesophagus. Lancet 360:1587–1589
12. Clement G, Braunschweig R, Pasquier N et al (2006) Alterations
of the Wnt signaling pathway during the neoplastic progression of
Barrett’s esophagus. Oncogene 25:3084–3092
13. Doucas H, Garcea G, Neal CP et al (2005) Changes in the Wnt
signalling pathway in gastrointestinal cancers and their prognostic
significance. Eur J Cancer 41:365–379
14. Shi XY, Bhagwandeen B, Leong AS (2008) p16, Cyclin D1, Ki-67,
and AMACR as markers for dysplasia in Barrett esophagus. Appl
Immunohistochem Mol Morphol 16:447–452
15. Shi XY, Bhagwandeen B, Leong AS (2008) CDX2 and villin are
useful markers of intestinal metaplasia in the diagnosis of Barrett
esophagus. Am J Clin Pathol 129:571–577
16. Nair KS, Naidoo R, Chetty R (2005) Expression of cell adhesion
molecules in oesophageal carcinoma and its prognostic value. J
Clin Pathol 58:343–351
17. Taketo MM (2006) Wnt signaling and gastrointestinal tumorigenesis
in mouse models. Oncogene 25:7522–7530
18. Okamoto R, Watanabe M (2004) Molecular and clinical basis for
the regeneration of human gastrointestinal epithelia. J Gastro-
enterol 39:1–6
19. Johnson ML, Rajamannan N (2006) Diseases of Wnt signaling.
Rev Endocr Metab Disord 7:41–49
20. van Es JH, van Gijn ME, Riccio O et al (2005) Notch/gamma-
secretase inhibition turns proliferative cells in intestinal crypts and
adenomas into goblet cells. Nature 435:959–963
21. Almeida R, Almeida J, Shoshkes M et al (2005) OCT-1 is over-
expressed in intestinal metaplasia and intestinal gastric carcinomas
and binds to, but does not transactivate, CDX2 in gastric cells. J
Pathol 207:396–401
22. Bian YS, Osterheld MC, Fontolliet C et al (2002) p16 inactivation
by methylation of the CDKN2A promoter occurs early during
neoplastic progression in Barrett’s esophagus. Gastroenterology
122:1113–1121
23. Brantjes H, Barker N, van Es J et al (2002) TCF: lady justice
casting the final verdict on the outcome of Wnt signalling. Biol
Chem 383:255–261
24. Yan P, Seelentag W, Bachmann A et al (2007) An agarose matrix
facilitates sectioning of tissue microarray blocks. J Histochem
Cytochem 55:21–24
25. Villanacci V, Rossi E, Zambelli C et al (2007) COX-2, CDX2, and
CDC2 immunohistochemical assessment for dysplasia-carcinoma
progression in Barrett’s esophagus. Dig Liver Dis 39:305–311
26. Bailey T, Biddlestone L, Shepherd N et al (1998) Altered cadherin
and catenin complexes in the Barrett’s esophagus-dysplasia-
adenocarcinoma sequence: correlation with disease progression
and dedifferentiation. Am J Pathol 152:135–144
27. Pinto D, Clevers H (2005) Wnt, stem cells and cancer in the
intestine. Biol Cell 97:185–196
28. Clevers H, Batlle E (2006) EphB/EphrinB receptors and Wnt
signaling in colorectal cancer. Cancer Res 66:2–5
29. Gregorieff A, Pinto D, Begthel H et al (2005) Expression pattern of
Wnt signaling components in the adult intestine. Gastroenterology
129:626–638
30. Mutoh H, Sakamoto H, Hayakawa H et al (2006) The intestine-
specific homeobox gene Cdx2 induces expression of the basic
helix-loop-helix transcription factor Math1. Differentiation
74:313–321
31. Liu T, Zhang X, So CK et al (2007) Regulation of Cdx2
expression by promoter methylation, and effects of Cdx2
transfection on morphology and gene expression of human
esophageal epithelial cells. Carcinogenesis 28:488–496
32. Greenawalt DM, Duong C, Smyth GK et al (2007) Gene
expression profiling of esophageal cancer: comparative analysis
of Barrett’s esophagus, adenocarcinoma, and squamous cell
carcinoma. Int J Cancer 120:1914–1921
33. Ngan CY, Yamamoto H, Seshimo I et al (1996) Expression of
CD44H and CD44v3 in normal oesophagus, Barrett mucosa and
oesophageal carcinoma. J Clin Pathol 49:489–492
34. Lagorce-Pages C, Paraf F et al (1998) Expression of CD44 in
premalignant and malignant Barrett’s oesophagus. Histopathology
32:7–14
35. Menges M, Goebel R, Pueschel W et al (2002) Expression of
CD44v5 and -v6 in Barrett’s carcinoma is not increased compared to
that in nondysplastic Barrett’s mucosa. Exp Mol Pathol 72:207–212
36. Niehrs C (2006) Function and biological roles of the Dickkopf
family of Wnt modulators. Oncogene 25:7469–7481
37. Sato H, Suzuki H, Toyota M et al (2007) Frequent epigenetic
inactivation of DICKKOPF family genes in human gastrointestinal
tumors. Carcinogenesis 28:2459–2466
38. Aguilera O, Fraga MF, Ballestar E et al (2006) Epigenetic
inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene
in human colorectal cancer. Oncogene 25:4116–4121
39. Ali I, Rafiee P, Hogan WJ et al (2006) Dickkopf homologs in
squamous mucosa of esophagitis patients are overexpressed
compared with Barrett’s patients and healthy controls. Am J
Gastroenterol 101:1437–1448
40. Van Baal JW, Bozikas A, Pronk R et al (2008) Cytokeratin and
CDX-2 expression in Barrett’s esophagus. Scand J Gastroenterol
43:132–140
41. Wegner M (1999) From head to toes: the multiple facets of Sox
proteins. Nucleic Acids Res 27:1409–1420
42. Blache P, van de Wetering M, Duluc I et al (2004) SOX9 is an
intestine crypt transcription factor, is regulated by the Wnt
pathway, and represses the CDX2 and MUC2 genes. J Cell Biol
166:37–47
43. Ferguson HR, Wild CP, Anderson LA et al (2008)
Cyclooxygenase-2 and inducible nitric oxide synthase gene
polymorphisms and risk of reflux esophagitis, Barrett’s esophagus,
and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers
Prev 17:727–731
44. Feith M, Stein HJ, Mueller J et al (2004) Malignant degeneration
of Barrett’s esophagus: the role of the Ki-67 proliferation fraction,
expression of E-cadherin and p53. Dis Esophagus 17:322–327
45. Wijnhoven BP, Nollet F, De Both NJ et al (2000) Genetic
alterations involving exon 3 of the beta-catenin gene do not play a
role in adenocarcinomas of the esophagus. Int J Cancer 86:533–
537
46. Williams LJ, Guernsey DL, Casson AG (2006) Biomarkers in the
molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
Curr Oncol 13:33–43
Virchows Arch (2009) 454:629–637 637
